Re: "A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder" by Strawn et al.-Concerning Harm-Benefit Ratio in a Recent Trial About Escitalopram for Generalized Anxiety Disorder.
Martin PlöderlMark A HorowitzMichael P HengartnerPublished in: Journal of child and adolescent psychopharmacology (2023)